Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 3/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | UBE2N | P61088 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16082980 | 0.90 | ATF4 (1.00) | ATF4KMT2ALMNARAB9AHPGD | |
| SCHEMBL16083047 | 0.90 | ATF4 (1.00) | ATF4KMT2ALMNARAB9AHPGD | |
| SCHEMBL16082988 | 0.90 | ATF4 (1.00) | ATF4KMT2ALMNARAB9AHPGD | |
| SCHEMBL19659841 | 0.86 | ATF4 (0.86) | ATF4KMT2ALMNARAB9AHPGD | |
| SCHEMBL19660078 | 0.86 | ATF4 (0.86) | ATF4KMT2ALMNARAB9AHPGD | |
| SCHEMBL17658492 | 0.86 | ATF4 (0.86) | ATF4KMT2ALMNARAB9AHPGD | |
| SCHEMBL17658626 | 0.86 | ATF4 (0.86) | ATF4KMT2ALMNAMEN1MAPK1 | |
| SCHEMBL17656861 | 0.86 | ATF4 (0.86) | ATF4KMT2ALMNARAB9AHPGD | |
| SCHEMBL17658616 | 0.85 | ATF4 (0.74) | ATF4KMT2ALMNARAB9AHPGD | |
| SCHEMBL17658630 | 0.85 | ATF4 (0.89) | ATF4KMT2ALMNARAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968347-B1 | MODULATORS OF THE EIF2ALPHA PATHWAY | UNIV CALIFORNIA (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11220477-B2 | Modulators of the eIF2alpha pathway | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-01-11 | — | — | US | disclosed |
| US-10343981-B2 | Modulators of the eIF2alpha pathway | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-09 | — | — | US | disclosed |
| US-20170342020-A1 | MODULATORS OF THE EIF2ALPHA PATHWAY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-11-30 | — | — | US | disclosed |
| US-9708247-B2 | Modulators of the eIF2alpha pathway | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160096800-A1 | MODULATORS OF THE EIF2ALPHA PATHWAY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342020-A1 | MODULATORS OF THE EIF2ALPHA PATHWAY | EIF2AK1, EIF2A, EIF2AK3 | ATF4 7/4885KMT2A 3254/4885LMNA 3251/4885 |
| US-11220477-B2 | Modulators of the eIF2alpha pathway | EIF2AK1, EIF2A, EIF2AK3 | ATF4 7/4885KMT2A 3254/4885LMNA 3251/4885 |
| US-20160096800-A1 | MODULATORS OF THE EIF2ALPHA PATHWAY | EIF2AK1, EIF2A, EIF2AK3 | ATF4 7/4885KMT2A 3254/4885LMNA 3251/4885 |
| US-10343981-B2 | Modulators of the eIF2alpha pathway | EIF2AK1, EIF2A, EIF2AK3 | ATF4 7/4885KMT2A 3254/4885LMNA 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.